Startseite Kongressberichte & Archiv All-Virtual 62nd ASH Annual Meeting and Exposition Oral Sessions Chronic Myeloid Leukemia Chronic Myeloid Leukemia

632. Chronic Myeloid Leukemia: Therapy— Building The Future CML

Watch Session

45 Nilotinib Vs. Dasatinib in Achieving MR4.5 for Newly Diagnosed Chronic Myeloid Leukemia: Results of the Prospective Randomized Phase 3 Study, JALSG CML212[nbsp]according to ASH clinically relevant abstract

Itaru Matsumura, Shigeki Ohtake, Yoshiko Atsuta, et al.

 

46 Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial according to ASH clinically relevant abstract

Tim H Brümmendorf, Jorge E. Cortes, Dragana Milojkovic, et al.

 

47 Do Not Miss Karyotyping at Chronic Myeloid Leukemia Diagnosis: An Italian Campus CML Study on the Role of Complex Variant Translocations according to ASH clinically relevant abstract
 
Massimiliano Bonifacio, Chiara Elena, Mariella D'Adda, et al.
 
 
 
48 Outcome By Mutation Status and Line of Treatment in Optic, a Dose-Ranging Study of 3 Starting Doses of Ponatinib in Patients with CP-CML

Jorge E. Cortes, Jane Apperley, FRCP, FRCPath, Andreas Hochhaus, et al.

 

49 Mutated Cancer-Related Genes Detected at Diagnosis of CML and a Novel Class of Variant Associated with the Philadelphia Translocation Are Both Independent Predictors of Inferior Outcomes according to ASH clinically relevant abstract

Naranie Shanmuganathan, Carol Wadham, Nur Hezrin Shahrin, et al.

 

50 Predictive Factors for Overall Survival in Chronic Myeloid Leukemia Patients: An Analysis By the Gimema Cml Italian Study according to ASH clinically relevant abstract

Giorgina Specchia, MD1, Patrizia Pregno2*, Massimo Breccia, et al.